Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pull $$$$$$
Reeling $$$$$ fish on $$$$$$$
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
https://ih.advfn.com/stock-market/NASDAQ/kintara-therapeutics-KTRA/stock-news/93560120/kintara-therapeutics-announces-expansion-of-rem-00
Announcement soon
Reeling $$$$$ tips down and reeling $$$$)
KINTARA
Therapeutics
Developing Advanced Oncology Therapies for Rare Unmet Medical Needs
Corporate Presentation
August 2023
Copyright © 2022 Kintara Therapeutics, Ir
EG
Robert Hoffman CEO
Late-stage Oncology Company with Two De-Risked Product Candidates
VAL-083: A first-in-class small molecule with unique MOA (MW = 146)
• Pivotal, pre-eminent GBM AGILE International registrational study for three GBM patient subtypes initiated January 2021. A total of 45 sites across US, Canada and Europe.
• ~$1B' market opportunity in lead program: Glioblastoma Multiforme (GBM)
- Multiple shots on goal via parallel enrollment of three GBM patient subtypes
- Over 1,200 patient safety database via ~40 prior studies
REM-001: 2nd generation photodynamic therapy platform
• National Institutes of Health grant awarded June 2023
• 15-patient confirmatory study to start this quarter (3Q 2023)
• ~$500M-market in lead program: Cutaneous Metastatic Breast Cancer
- Extensive Phase 2/Phase 3 efficacy data (80% complete responses across four trials)
- Over 1,100 patient safety database
Multiple follow-on indications with existing orphan designations and/or approved INDs
*Charles River Associates April 2018
EG
Robert Hoffman CEO
Photodynamic Therapy Mechanisms of Action
Light
Energy Source
Necrosis
+
+
10,
Photosensitizen
Catalyst to Activate, Absorb &
Transfer Energy to Oxygen in Cells
Oxygen in Cell
Converted to ROS by Energy Transfer
Reactive 02 (ROS)
Created by
Energy Transfer
PDT induces elimination of diseased cells by
immune response, apoptosis, antiangiogenesis and necrosis
Apoptosis
Antiangiogenic / Anti-vascular
Vascularized,
POT Impairs Vessel
Anglogenic Tumor Function to Cut Off
Blood Supply
Tumor Shrinks
T - Cell Response
Local POT
Tumor
Diseased Cell Death
ROS Provides
Mechanism of Action
Antigen
Metastic
marin
Enzymatic Digestion and
Phagocytosis of Apoptotic
EG
Robert Hoffman CEO
Complete Response Rate of Evaluable Lesions
100
80
60
40
20
71%
CA008
REM-001: High Response Rates in CMBC
97%
86%
80%
54%
• REM-001
= Control
????
Combined
Prior Clinical Trials
Second Generation Photodynamic Therapy
• Light activated cancer therapy
Extensive data from prior Phase 2/Phase 3 clinical trials
• 149 patients treated in 4 trials
- 80% complete response rate in 674
evaluable lesions
Localized Outpatient Treatment
• IV drug infusion accumulates in tumors
• Activated by simple red light
Safety database ~1,100 patients
Previous trial experience used to optimize current trial design
EG
Robert Hoffman CEO
REM-001: CMBC Development Plan
Development plan optimized for success while minimizing cost
• Phase 3 ready
• Initial open-label, 15-patient study to confirm lower dose and optimize trial design
• Leverages prior data indicating lower dose can improve outcome
- Faster healing
- Less photosensitivity
• De-risks full Phase 3 study
IND reactivated August 2022
Fast Track designation received from the FDA in November 2022
National Institutes of Health Grant awarded June 2023
BG
3 Fast track Drug Designations From FDA
1 - 3 Types of Glioblastoma - $ 1.0 B Market & 1 Metastatic Breast Cancer $ 500 Market
wait till close/thur morn for your answer we shall see
Ain’t skeerd here cosm,lifw started down here
Hey TCON was down here at this level
I’ve added big
descending wedges are normally very big movers
moon market just mention this lol
Right sector $$$$
Fish hit reeling $$$$$$
Could be a really good day here today!
8,000,000 to put to work $$$$$$ set the hook FISH ON $$$$$$$$ let’s go $$$$$
$KTRA LOLOLOLOL MM's are "F" ing with this soooooo bad....it is actually becoming HILARIOUS....their efforts to shake us out / free is becoming monumental.... that and them keeping the SPREAD so big at such low levels hang tight there peeps...This morning in the PRE, PRE-market $KTRA was popped up to over .1347 This is hilarious
Wondering who the buyer of the offer will be.
Yes.... but you made me SEARCH the site FOR it ??? lololol
Fibrobiologics announces direct listing on nasdaq under the stock ticker FBLG
FBLG inaugural Board of Directors...Check out KTRA CEO Robert E. Hoffman
FibroBiologics Announces Direct Listing on NASDAQ ...
PR Newswire
https://www.prnewswire.com › news-releases › fibrobi...
FibroBiologics Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG. The future of chronic disease cures and cell therapy. (PRNewsfoto/FibroBiologics) ...
$KTRA Whelp folks... Been "wrenching" on the DD for $KTRA Yes there are MANY shares available to borrow and short and THAT in and OF itself is rather criminal...but the ACTUAL # of shares short currently are negligible. The "Days to cover" is between .05 - 1 Day...That nothing...so...not expecting a "squeeze"...
It is now my firm, experienced belief that $KTRA is being manipulated and being "held down" on purpose for reasons of "accumulation" at these "sub .25" levels.
Everyone knows the "nano-float" on this ticker...I believe the sudden climbs yesterday were an "info leak" which caught MM's off guard... The coming news which WILL Rocket $KTRA is either word on their remaining treatment ready for Phase III OR it's word on a "merger / buyout".
Robert E. Hoffman is CEO of $KTRA and on the board of newly NAZ public $FBLG . The "DOTS" are connecting. I believe $KTRA will soon be found!
That is MY DD understanding of the existing float as well 3.38 Mill...
KTRA - very nice volume everyday making us conclude it is getting loaded for a big event better than a pump and dump.
ktra market cap. Les than half a million. Heavily shorted. And 3 months ago was trading at 4 all the ingredients for a mega squeeze in my opinion . No selling for pennies here
Market Cap 530,870 01/05/2024..........................
...yea right, OTCMarkets is a little off on this one.
So, What is the friggin float here?
Through the date hereof (12/18), we have sold an aggregate of 5,537,589 shares of Common Stock
The Prospectus Supplement relates to the offering by the Company of up to $8,700,000 in shares of the common stock of the Company, par value $0.001 (the “Shares”), covered by the Registration Statement. The Shares are being offered and sold by A.G.P./Alliance Global Partners as sales agent (the “Sales Agent”) pursuant to the Sales Agreement between the Company and the Sales Agent dated September 19, 2023 (the “Sales Agreement”).
Number of shares of common stock outstanding as of November 13, 2023 was 3,387,808.
How come??
10q .... Number of shares of common stock outstanding as of November 13, 2023 was 3,387,808.
Todays volume 7,769,209
I think I missed something in my hasty research before I took a position here.
Looks like I’m buying down here. Volume is crazy!!!! This is bound for some type of reversal just based on volume and current price point.
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1415
|
Created
|
01/25/13
|
Type
|
Free
|
Moderators |
https://www.kintara.com/
Kintara Therapeutics is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for development in indications with established biomarkers, and where patients are failing, or are unable to tolerate, current therapies.
VAL-083 is a "first-in-class" small molecule chemotherapeutic. Its unique structure provides many valuable benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier, critical for activity against central nervous system (CNS) tumors.
VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory glioblastoma multiforme (GBM) and is currently being studied in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.
We are also pursuing the development of VAL-083 in the treatment of ovarian cancer.
REM-001 has broad utility for the treatment of serious cutaneous oncology indications. REM-001 has been previously studied in four Phase 2 and/or Phase 3 clinical trials in patients with cutaneous metastatic breast cancer (“CMBC”), who had previously received chemotherapy and/or failed radiation therapy.
Zacks Small-Cap Research
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_10112021_KTRA_Vandermosten.pdf
Based on our DCF model and a 15% discount rate, Kintara Therapeutics is valued at approximately $5.25 per share. Our model applies a 60% probability for VAL-083 in unmethylated GBM, a 50% probability in methylated GBM and a 50% probability of approval and commercialization in REM-001 for CMBC. The model includes contributions from the United States and Europe. Other regions will be included upon further clarity.
Shares Outstanding (mil) 43.2
Current Price (10/8/2021) $0.77
Valuation $5.25.
11/03/21
Thanks to its promising pipeline and $0.88 share price, 5-star analyst Michael King, of
H.C. Wainwright, sees an attractive entry point for investors.
“We are bullish about KTRA shares for the following five reasons
: (1) The GBM AGILE trial tests VAL-083 in
all three subtypes of GBM, allowing for multiple opportunities for VAL-083 to prove its
efficacy against phenotypically distinct types of the disease.
(2) VAL-083 is a bifunctional
alkylating agent that crosses the blood brain barrier and exhibits very favorable pharmacologic
properties relative TMZ; fulfilling the need for systemic availability in the brain.
(3) VAL-083
has an established favorable safety record, both from initial trials and prior clinical use in
multiple indications.
(4) Dire unmet need in GBM may present relatively low bar for approval.
(5) Phase 3 ready REM-001 is an additional bonus which is not factored into our valuation
assumptions and could potentially deliver value to shareholders while providing a backstop
against downside,” King explained.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |